



(51) International Patent Classification:

A61K 31/439 (2006.01) A61P 25/34 (2006.01)
A61K 9/36 (2006.01) C07D 221/06 (2006.01)
C07C 243/06 (2006.01) C07D 471/12 (2006.01)
C07D 221/22 (2006.01) C07D 471/14 (2006.01)
A61K 31/435 (2006.01) C07D 471/18 (2006.01)

(21) International Application Number:

PCT/US2024/059590

(22) International Filing Date:

11 December 2024 (11.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/608,935 12 December 2023 (12.12.2023) US

(71) Applicant: **ACHIEVE LIFE SCIENCES, INC.** [US/US];
22722 29th Dr. SE, Suite 100, Bothell, Washington 98021
(US).

(72) Inventors: **DELGADO RUEDA, Marco Antonio**; 61
Cophall Lane, Chalfont St Peter, Bucks Buckinghamshire
SL90DS (GB). **MILLER, Kelly**; c/o Achieve Life
Sciences, Inc, 22722 29th Dr. SE, Suite 100, Bothell, Wash-
ington 98021 (US). **DONNELLY, Craig**; c/o Achieve Life

Sciences, Inc., 22722 29th Dr. SE, Suite 100, Bothell,
Washington 98021 (US). **ELDER, David**; Cerebro CMC
Limited, Stevenage Bioscience, Catalyst, Incubator Build-
ing, Gummels Wood Road, Stevenage Hertfordshire SG1
2FX (GB). **SEARLE, Andrew**; Cerebro CMC Limited,
Stevenage Bioscience, Catalyst, Incubator Building, Gun-
nels Wood Road, Stevenage Hertfordshire SG1 2FX (GB).

(74) Agent: **FOURNIER, David** et al.; P.O. Box 1247, Seattle,
Washington 98111-1247 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: SMOKING CESSATION COMPOUNDS HAVING REDUCED NITROSAMINES AND ASSOCIATED METHODS




FIG. 1

(57) Abstract: Provided herein is a pharmaceutical composition comprising cyti-
sine and a nitrite scavenger, wherein, upon storage of the composition at about
60 °C, the amount of N-nitrosocytisine relative to a total weight of cytosine is 4.2
ng/mg or less after about 30 days. A method of manufacturing a cytosine tablet
is also provided.

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*